Ropeginterferon alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes

Table 1 Characteristics of Included Studies

Ref.	Country	Study period (year)	Study design	Sample size (ropeginterferon; standard)	Male sex, % (ropeginterferon; standard)	Outcomes reported
Barbui et al[20], 2023	Italy	2	RCT	64; 63	73.4 (47/64); 61.9 (39/63)	CHR, molecular response, AEs leading to discontinuation, thrombotic events, change in JAK2V617F allele burden, number of phlebotomies per patient-year
Barbui et al[19], 2024	Italy	5	RCT	64; 63	73.4 (47/64); 61.9 (39/63)	CHR, AEs leading to discontinuation, thrombotic events, number of phlebotomies per patient-year
Gisslinger et al[22], 2020 (P)	Europe	3.5	RCT	127; 127	46.5 (59/127); 47.2 (60/127)	CHR, molecular response, AEs leading to discontinuation, thrombotic events, change in JAK2V617F allele burden
Gisslinger et al[22], 2020 (C)	Europe	5	RCT	95; 76	50.5 (48/95); 52.6 (40/76)	CHR, molecular response, thrombotic events, change in JAK2V617F allele burden
Kiladjian et al[18], 2022 (P)	Europe	5	RCT	127; 127	46.5 (59/127); 47.2 (60/127)	CHR, molecular response, AEs leading to discontinuation, thrombotic events, change in JAK2V617F allele burden

RCT: Randomized controlled trial; CHR: Complete hematological response; AEs: Adverse events; P: PROUD-PV phase; C: CONTINUATION-PV phase.